This resource describes how state health departments and other public health organizations can partner with people with HIV and/or who use(d) drugs in programmatic and policy making processes and evaluation.
Breadcrumb
- Home
- Resources and Tools
Resources and Tools
Articles in this supplement focus on the global opioid crisis, including coverage of harm reduction approaches, health justice promotion, and lessons learned.
The COVID-19 pandemic resulted in federal policy changes related to telehealth use that allowed states to maximize access to medications for opioid use disorder (MOUD) through telehealth.
Individuals who have HIV who also use drugs experience increased age-matched morbidity and mortality in comparison with those with HIV who do not use drugs.
This discussion guide is intended to elicit a comprehensive and concrete conversation about language, stigma, and discrimination as a means of strengthening care systems and ensuring that people who seek care for HIV and/or substance use disorders, including opioid use disorder, are treated with
A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
In recent years, the gap in the rate of opioid overdoses among Black and white Americans has narrowed significantly, with increases in Black mortality driven in part by the addition of synthetic opioids to other drugs.
Opioid agonist treatment (OAT) is the provision of medications (methadone and buprenorphine) that activate the opioid receptors to prevent withdrawal and reduce cravings for opioids.
This publication, part of SAMHSA's Evidence Based Resource Guide series, addresses the co-occurrence of HIV and mental illness and/or SUD.
Pagination
- Page 1
- Next page ››